The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
Biomarker Technologies (China) · Roche (Switzerland)
Abstract
Clinical trials with immune checkpoint inhibitors have provided important insights into the mode of action of anticancer immune therapies and potential mechanisms of immune escape. Development of the next wave of rational clinical combination strategies will require a deep understanding of the mechanisms by which combination partners influence the battle between the immune system's capabilities to fight cancer and the immune-suppressive processes that promote tumor growth. This review focuses on our current understanding of tumor and circulating pharmacodynamic correlates of immune modulation and elaborates on lessons learned from human translational research with checkpoint inhibitors. Actionable tumor…
Citation impact
- FWCI
- 28.46
- Percentile
- 100%
- References
- 86
Authors
3Topics & keywords
- Immune system
- Immunotherapy
- Cancer immunotherapy
- Tremelimumab
- Immune checkpoint
- Cancer
- Medicine
- Clinical trial